Based on scientific evaluation, potential health risk and therapeutic benefit, the ECDD recommends the appropriate classification of psychoactive substances within them. After using cannabis, people should not drive during the period of acute psychoactive effects. In individual patients, more frequent follow-up may be necessary, especially at the beginning of medical treatment with cannabis. The modified Delphi process was also applied in this report to pragmatically align how to adjust the consumption of medical cannabis and, at the same time, reduce the dose of opioids.
Unlike THC, CBD's mechanism of action is not thought to be primarily due to its binding to the cannabinoid receptor. The June meeting, in preparation for the vote scheduled for December, was the “first thematic meeting in a series of three at which countries will discuss the economic, legal, administrative and other implications of the adoption of the six WHO proposals on cannabis”. The adoption of Recommendation 5.1 has broad symbolic meaning for medical cannabis, as it could help boost efforts to legalize medical cannabis around the world now that the CND tacitly recognizes the medical utility of the drug. The risk of collision is even greater when cannabis and alcohol are consumed together, since the combination of these drugs amplifies the effects of deterioration.
Consensus-based recommendations for adjusting the size of cannabinoids and reducing the dose of opioids for the control of chronic pain. Cannabis users should be aware of the nature and composition of the cannabis products they consume. In this context, the primary objective of Canada's Low-Risk Cannabis Use Guidelines (LRCUG) is to provide science-based recommendations to enable people to reduce their health risks associated with cannabis use, similar to the intention of health-oriented guidelines for the use of alcohol, nutrition, or low-risk sexual intercourse behavior. The panel was selected based on clinical experience in prescribing medical cannabis, research with medical cannabis and the focus on including representatives from different countries.
Following recruitment, working group participants completed a survey on practice patterns (additional file) to gain information on how doctors around the world treated patients with medical cannabis. Two of the World Health Organization (WHO) recommendations for cannabis programming could face an uphill battle and be adopted later this year by the United Nations Commission on Narcotic Drugs (CND). The apparent lack of verbal support is a worrying sign for cannabis companies hoping to capitalize on this possible international change that would clarify that certain CBD products are not subject to the controls of the 1961 Single Convention. Studies show that starting cannabis use at an early age, mainly before age 16, increases the risk of a variety of adverse health outcomes.
Other versions of the LRCUG, such as a brochure aimed primarily at cannabis consumers, are available on camh.
Leave a Comment